– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the way for Phase 1 clinical trial
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here